(NSE) – Press Releases
-
Biocon Biologics Secures US Market Entry Date for Bmab 1200, a Proposed Biosimilar to Stelara®
-
Biocon Biologics Partners with Sandoz Australia for Biosimilars Trastuzumab and Bevacizumab
-
Biocon Biologics Successfully Completes Integration of Viatris' Biosimilar Business in 31 Countries in Europe
-
Biocon Biologics Continues to Expand Global Footprint, Completes Integration of Viatris Biosimilars' Business In North America Ahead of Schedule
-
Biocon Biologics Announces Positive CHMP Opinion for YESAFILI®, Biosimilar Aflibercept
-
AFTER FIVE YEARS OF SUCCESSFUL EXPERIENCE INTERNATIONALLY, BIOCON BIOLOGICS' HULIO® BIOSIMILAR TO HUMIRA®, NOW AVAILABLE IN THE UNITED STATES
-
Equillium’s Partner Biocon Initiates Phase 2 Study of Itolizumab in Ulcerative Colitis
-
Termination of Agreement to Acquire BillDesk
-
Alvotech, a Global Pureplay Biosimilars Company, to Debut on Nasdaq Under the Ticker ALVO on June 16
-
STADA and Alvotech broaden European patients’ options by launching Hukyndra® high-concentration, citrate-free adalimumab
-
Alvotech and Oaktree Acquisition Corp. II Announce Shareholder Approval of Business Combination
-
Viatris and Biocon Biologics Announce Launch of Interchangeable SEMGLEE® (insulin glargine-yfgn) Injection and Insulin Glargine (insulin glargine-yfgn) Injection
-
Viatris Inc. and Biocon Biologics Receive Historic Approval for First Interchangeable Biosimilar Semglee® (insulin glargine-yfgn injection) for the Treatment of Diabetes
-
Infosys positioned as a Leader in Application Modernization and Migration Services as Enterprises shift to Cloud-native technologies for their Modernization needs
-
Mylan and Biocon Biologics Announce Launch of Semglee™ (insulin glargine injection) in the U.S. to Expand Access for Patients Living with Diabetes
-
Biocon Biologics and Voluntis Join Hands for Global Collaboration on Digital Therapeutics for Insulins
-
Mylan and Biocon Announce U.S. FDA Approval of Semglee™ (insulin glargine injection)
-
Vakrangee Ranked World's No.1 Company in the Software and Services Industry Based on Sustainalytics ESG Assessment
-
New Stratus Energy Announces Amendment of Warrants
-
Sun Pharmaceutical Industries, Inc. Donates 2.5 Million Hydroxychloroquine Sulfate Tablets in the U.S. For Potential COVID-19 Treatment
-
U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Bevacizumab for Review
-
Sun Pharma Launches RIOMET ER Oral Suspension in the U.S.
-
Mylan and Biocon Launch Trastuzumab Biosimilar, Ogivri™ (trastuzumab-dkst), in the U.S.
-
New Stratus Energy Files Amended Financial Statements and Announces Board and Management Changes
-
Sun Ophthalmics to Present Updated CEQUA™ and XELPROS™ Data at AAOPT/WCO 2019
-
Mylan and Biocon to Present Final Overall Survival Data for Ogivri™ (trastuzumab-dkst), a biosimilar to Herceptin®, at the American Society of Clinical Oncology (ASCO) Annual Meeting
-
Mylan and Biocon Announce Positive CHMP Opinion for Ogivri®, Biosimilar Trastuzumab
-
Mylan and Biocon Announce Positive CHMP Opinion for Fulphila®, Biosimilar Pegfilgrastim
-
U.S. FDA Approves Mylan and Biocon's Fulphila™ (pegfilgrastim-jmdb), the First Biosimilar to Neulasta®
-
Mylan and Biocon to Present New Data at the American Society of Clinical Oncology (ASCO) Annual Meeting Reinforcing the Efficacy, Safety and Immunogenicity of Ogivri™, the first biosimilar for Herce
-
New Stratus Energy Announces Proposed Acquisition and Private Placement Offering of Subscription Receipts
-
New Stratus Energy Announces Proposed Acquisition and Private Placement Offering of Subscription Receipts
-
Mylan and Biocon Receive Approvals from the European Commission and TGA Australia for Semglee™, Biosimilar Insulin Glargine
-
New Stratus Energy Announces Amendment of Warrants
-
CytoSorbents Expands Its Partnership with Biocon to Launch CytoSorb® in Malaysia
-
Mylan and Biocon Receive Positive CHMP Opinion for Semglee™, Biosimilar Insulin Glargine
-
Biocon and Mylan's Biosimilar Trastuzumab Receives Approval from ANVISA, Brazil Through their Partner Libbs
-
U.S. FDA Approves Mylan and Biocon's Ogivri™, the First Biosimilar for Trastuzumab, for the Treatment of HER2-Positive Breast and Gastric Cancers
-
European Medicines Agency Accepts Marketing Authorization Applications for Mylan and Biocon's Proposed Biosimilars Trastuzumab and Pegfilgrastim
-
Quark Pharmaceuticals, Inc. to Present Preclinical Efficacy Data on Inhaled siRNA Co-Developed with Biocon for Prevention of Primary Graft Dysfunction following Lung Transplantation at the 6th Annual
-
FDA Oncologic Drugs Advisory Committee Unanimously Recommends Approval of Mylan and Biocon's Proposed Biosimilar Trastuzumab
-
Mylan and Biocon Present Clinical Data on Insulin Glargine at the American Diabetes Association's 77th Scientific Sessions
-
Dalmia Cement Partners for India's Longest Bridge
-
U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Pegfilgrastim for Review
-
U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Trastuzumab
-
Journal of the American Medical Association (JAMA) Publishes Mylan and Biocon's Proposed Biosimilar Trastuzumab Phase 3 Data
-
Mylan and Biocon Announce U.S. FDA Submission for Proposed Biosimilar Trastuzumab
-
Mylan and Biocon Announce Regulatory Submission for Insulin Glargine Accepted for Review by European Medicines Agency
-
Syngene International Commissions Dedicated R&D Center for Amgen
-
Mylan and Biocon Announce Regulatory Submission for Proposed Biosimilar Trastuzumab Accepted for Review by European Medicines Agency
Back to NSE Stock Lookup
